A Phase 1/2 Study of the Safety and Preliminary Activity of MYDICAR at a Dose of 2.5 x 10^13 DNase Resistant Particles (DRP) in Subjects With Advanced Heart Failure Divided Into 2 Phases: Phase 1 Open-label and Phase 2 Randomized, Double-blind, Placebo-controlled

Trial Profile

A Phase 1/2 Study of the Safety and Preliminary Activity of MYDICAR at a Dose of 2.5 x 10^13 DNase Resistant Particles (DRP) in Subjects With Advanced Heart Failure Divided Into 2 Phases: Phase 1 Open-label and Phase 2 Randomized, Double-blind, Placebo-controlled

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs SERCA 2a gene therapy (Primary)
  • Indications Heart failure
  • Focus Adverse reactions
  • Sponsors Celladon
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 26 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top